SOLUTION-Pilot 1.0
Research type
Research Study
Full title
Standard of care Or weight Loss drUg Therapy In Obesity-related hypertensioN Pilot study
IRAS ID
362166
Contact name
James Goodman
Contact email
Sponsor organisation
Cambridge University Hospitals NHS Foundation Trust
Duration of Study in the UK
1 years, 0 months, 0 days
Research summary
What is the research question?
New data suggest that intensive weight loss elicited by the new anti-obesity drugs could be effective in managing overweight or obesity-related high blood pressure (hypertension). The aim of this feasibility study is to assess the extent and trajectory of blood pressure reduction achieved through intensive weight loss (elicited by tirzepatide, a GLP-1/GIP receptor dual agonist) in overweight or obese young individuals with stage 1 hypertension.What is being studied?
The effects of intensive weight loss (elicited by tirzepatide) and our current antihypertensive pathways/guidelines on blood pressure.Who is eligible?
Young (18-40 years) individuals with overweight/obesity (body mass index ≥27 kg/m2) and stage 1 hypertension (unattended brachial systolic blood pressure ≥135 and/or diastolic blood pressure ≥85 mmHg and <160/100 mmHg).Where will the study take place?
The study will be conducted at Addenbrooke's Hospital (Cambridge University Hospitals NHS Foundation Trust) in
Cambridge.How long will the study last?
The expected duration of the study is 12 months. In the Weight loss arm, participants will undergo six visits over six months. Participants in the Standard of care arm will have one clinical visit combined with a research visit.REC name
Wales REC 6
REC reference
25/WA/0268
Date of REC Opinion
11 Nov 2025
REC opinion
Further Information Favourable Opinion